STEVENSON, Md., Feb. 08, 2016 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Insys Therapeutics, Inc. (Nasdaq:INSY) (“Insys” or the “Company”) common stock during the period between March 3, 2015 and January 25, 2016, inclusive (the “Class Period”). Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until April 4, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Insys common stock purchased on or after March 3, 2015 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company common stock during the Class Period. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company was engaged in the illegal and improper off-labeling marketing of Subsys and that certain Insys employees’ were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys.
According to the complaint, following the January 25, 2016 revelation that Insys executives continued to pressure Company employees to develop new schemes to promote the illegal and improper off-label marketing and sale of Subsys, the value of Insys shares declined significantly.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



